Page 4 - BLADDER CANCER
P. 4
Advanced Urothelial Carcinoma
Current Treatment Landscape
• First-line: Platinum-based chemotherapy
• Response rates 40-60%
• Second-line: PD-1/PDL-1 Inhibitors
• Pembrolizumab has a survival benefit
• Durable responses occur, but only in a minority of patients
• Coming soon: First-line maintenance therapy
• Avelumab in patients with stable disease / response to platinum-
based chemotherapy. (Health Canada approved, pending
access)